CNOT3

Across TCGA pan-cancer cohorts, CNOT3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CNOT3 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CNOT3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CNOT3 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where CNOT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.248	0.580	.023	7	view →
HNSC	DFS	Quartile	IV	0.596	0.832	.029	4	view →
GBM	OS	Quartile	All	0.570	0.321	.022	4	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CNOT3–PDAC (OS)

Open the PDAC breakdown →